Researchers have no way to determine how significant the problem of substance abuse and pregnancy really is. Very few women will be open and honest when it comes to answering questions about elicit drug use. So how do doctors get their patients the proper help? Dr. Mishka Terplan, an associate professor at the University of Chicago, looks at the issues of universal drug screening for all pregnant women, confidentiality, inpatient and outpatient drug rehabilitation programs and the stigma of being a substance abuser, with host Dr. Lisa Mazzullo.
Managing Dual Conditions in Pregnant Substance Abusers

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Researchers have no way to determine how significant the problem of substance abuse and pregnancy really is. Very few women will be open and honest when it comes to answering questions about elicit drug use. So how do doctors get their patients the proper help? Dr. Mishka Terplan, an associate professor at the University of Chicago, looks at the issues of universal drug screening for all pregnant women, confidentiality, inpatient and outpatient drug rehabilitation programs and the stigma of being a substance abuser, with host Dr. Lisa Mazzullo.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
FCS and SHTG: Are We Meeting the Need?
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
Level Up Your Skills: Tailoring Management of HF
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
NYHA FC and Finerenone Response: Clinical Trial Insights
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?